Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03616834 · ClinicalTrials.gov registry record · Phase 2
Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy
A Phase 2 study, sponsored by Effector Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT03616834: Completed Phase 2 study, sponsored by Effector Therapeutics.
NCT03616834 is a Phase 2 study that has completed, run by Effector Therapeutics. The registered enrollment target is 39 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03616834, a Phase 2 study, has completed, sponsored by Effector Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
Phase 2, open-label study that will evaluate the safety, tolerability, antitumor activities.
Primary Outcome
The incidence of TEAEs and SAEs will be summarized and TEAEs will also be summarized by severity and according to their relationship to Tomivosertib (eFT-508).
Interventions
- DRUG Tomivosertib (eFT-508)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2018-07-25 |
| Est. Completion | 2021-06-30 |
| Phase | Phase 2 |
What the finished NCT03616834 record still lists
NCT03616834 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower).
The record links to 0 conditions, and to 1 intervention - of which Tomivosertib (eFT-508) is the first listed.
NCT03616834 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03616834 about?
NCT03616834 is a clinical study titled "Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy". Phase 2, open-label study that will evaluate the safety, tolerability, antitumor activities.
What is the current status of trial NCT03616834?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2018-07-25. Estimated completion is 2021-06-30.
What interventions are being tested in trial NCT03616834?
The interventions under investigation include: Tomivosertib (eFT-508) (DRUG).
Who is sponsoring clinical trial NCT03616834?
This trial is sponsored by Effector Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03616834's enrollment target sits among peer trials
39 1459th of 2000 higher than 534 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI